Champions Oncology, Inc. (CSBR) Stock Price

CSBRStock

$4.70−28.57%52W

Market Cap$65.42M

P/E15.84x

PEG Ratio—

Div yield—

Beta0.41

CSBR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-27.88%

Price vs S&P 500 (4W)-9.32%

VGM Score47.78

P/E Ratio (Annual)15.84x

P/CF (Annual)10.08x

Book Value / Share (Quarterly)$0.28

P/TBV (Annual)17.39x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)3.33%

Cash Flow / Share (Quarterly)$-0.44

Price vs S&P 500 (YTD)-43.70%

Gross Margin (TTM)49.82%

Net Profit Margin (TTM)-1.82%

EPS (TTM)$-0.08

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-0.08

Revenue Growth (5Y)7.68%

EPS (Annual)$-0.08

ROI (Annual)-29.19%

Gross Margin (Annual)48.00%

Net Profit Margin (5Y Avg)-3.40%

Cash / Share (Quarterly)$0.31

P/E Basic Excl Extra (TTM)32.38x

Revenue Growth QoQ (YoY)8.84%

P/E Normalized (Annual)15.84x

ROA (Last FY)-4.35%

Revenue Growth TTM (YoY)6.65%

EBITD / Share (TTM)$0.02

ROE (5Y Avg)-1.88%

Operating Margin (TTM)-1.68%

Cash Flow / Share (Annual)$-0.36

P/B Ratio16.80x

P/B Ratio (Quarterly)19.13x

Net Income / Employee (Annual)$-5,500

EV / Revenue (TTM)1.01x

Net Interest Coverage (TTM)-6.62x

ROA (TTM)-3.71%

EPS Growth QoQ (YoY)-64.35%

EV / EBITDA (TTM)197.24x

EPS Incl Extra (Annual)$-0.08

Current Ratio (Annual)0.96x

Quick Ratio (Quarterly)0.96x

3-Month Avg Trading Volume0.01M

52-Week Price Return-28.57%

EV / Free Cash Flow (Annual)9.64x

P/E Incl Extra (TTM)32.38x

Revenue / Employee (TTM)$284,800

Tangible BV / Share (Quarterly)$0.70

P/S Ratio (Annual)1.10x

Asset Turnover (Annual)2.20x

52-Week High$8.31

Operating Margin (5Y Avg)-3.42%

EPS Excl Extra (Annual)$-0.08

CapEx CAGR (5Y)-29.68%

26-Week Price Return-17.98%

Quick Ratio (Annual)0.91x

13-Week Price Return-23.33%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)1.03x

Enterprise Value$61.34M

Revenue / Share Growth (5Y)8.81%

Asset Turnover (TTM)2.04x

Book Value / Share Growth (5Y)-7.45%

Revenue / Employee (Annual)$279,000

Inventory Turnover (Annual)50.00x

Pretax Margin (Annual)-1.56%

Cash / Share (Annual)$0.35

3-Month Return Std Dev44.03%

Gross Margin (5Y Avg)47.32%

Net Income / Employee (TTM)$-5,200

EBITDA CAGR (5Y)-31.31%

EBITDA Interim CAGR (5Y)-44.90%

ROE (Last FY)-29.83%

Net Interest Coverage (Annual)-2.54x

EPS Basic Excl Extra (Annual)$-0.08

P/FCF (TTM)8.59x

Receivables Turnover (TTM)5.26x

EV / Free Cash Flow (TTM)17.67x

Total Debt / Equity (Quarterly)0.07x

EPS Incl Extra (TTM)$-0.08

Receivables Turnover (Annual)4.87x

ROI (TTM)-26.13%

P/S Ratio (TTM)1.08x

Pretax Margin (5Y Avg)-3.32%

Revenue / Share (Annual)$4.30

Tangible BV / Share (Annual)$0.70

Forward P/E47.00x

Free OCF CAGR (5Y)58.93%

Price vs S&P 500 (52W)-44.10%

P/E Ratio (TTM)32.38x

Year-to-Date Return-31.98%

5-Day Price Return-5.11%

EPS Normalized (Annual)$-0.08

ROA (5Y Avg)-6.33%

Net Profit Margin (Annual)-1.98%

Month-to-Date Return-6.00%

Cash Flow / Share (TTM)$-0.32

EBITD / Share (Annual)$0.02

EPS Growth (3Y)104.02%

Operating Margin (Annual)-1.92%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)16.95x

ROI (5Y Avg)-3.13%

P/E Excl Extra (TTM)32.38x

LT Debt / Equity (Quarterly)0.02x

EPS Basic Excl Extra (TTM)$-0.08

P/TBV (Quarterly)17.39x

P/B Ratio (Annual)21.01x

Inventory Turnover (TTM)50.40x

Pretax Margin (TTM)-1.47%

Book Value / Share (Annual)$0.28

Price vs S&P 500 (13W)-26.01%

Beta0.41x

P/FCF (Annual)9.35x

Revenue / Share (TTM)$4.36

ROE (TTM)-27.12%

52-Week Low$4.59

vGradeC

gGradeC

mGradeC

vgmGradeC

CSBR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Dec 15, 2025	$0.00	$0.06	+0.00%(+$0.06)
Q2 2025	Sep 15, 2025	-$0.01	$0.02	+300.00%(+$0.03)
Q1 2025	Jul 23, 2025	-$0.20	-$0.12	+38.09%(+$0.08)
Q4 2024	Mar 11, 2025	-$0.01	$0.33	+3400.00%(+$0.34)

CSBR Analyst Recommendations

Apr 2026

May 2026

Jun 2026

Jul 2026

4.14

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CSBRChampions Oncology, Inc.	C	C	C	1.1x	6.7%	49.8%	—	$4.70
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About Champions Oncology, Inc.

Champions Oncology provides precision medicine technology for oncology drug development and personalized cancer treatment. Its Personalized Oncology Solutions segment delivers tumor-specific genomic data to physicians for treatment customization, while its Translational Oncology Solutions segment supports pharmaceutical companies with tumor specimens and research services for drug development. The company generates revenue primarily through research services to both healthcare providers and biopharma clients.